III. CLAIM AMENDMENTS

1-25. (Cancelled)

26. (New) Use of at least one of the 2,5-dihydroxybenzenesulfonic compounds of general formula I,

wherein

R represents H or SO₃-,

B represents at least one cation

n represents 1 or 2

m represents 1 or 2,

optionally in form of a pharmaceutically acceptable solvate, for the manufacture of a medicament for the prophylaxis and/or treatment of sexual dysfunction in humans, whereby the medicament is administered in a daily dose of the afore mentioned compounds of formula I of <500 mg.

- 27. (New) Use according to claim 26, characterised in that the cation(s) B is (are) selected from the group consisting of Ca^{2+} , Mg^{2+} , Na^+ , K^+ and $[NH_{4-x}R_X]^+$, whereby x is 0, 1, 2, 3, or 4 and R represents a branched or unbranched C_{1-4} -alkyl-radical that may be the same or different for x>1.
- 28. (New) Use according to claim 26, characterized in that the compound of general formula I is calcium 2,5-dihydroxybenzenesulfonate (calcium-dobesilate).
- 29. (New) Use according to claim 26, characterized in that the compound of general formula I is diethylamine 2,5-dihydroxybenzenesulfonate (ethamsylate).
- 30. (New) Use according to claim 26, characterized in that the compound of general formula I is bis(diethylamine)-2,5-dihydroxybenzene-1,4-disulfonate (persilate).
- 31. (New) Use according to claim 26, characterized in that medicament is administered in a daily dose of compounds of general formula I of 100 to <500 mg, preferably 150 to 450 mg, particularly preferably 200 to 400 mg.
- 32. (New) Use according to claim 26 for the prophylaxis and/or treatment of erectile dysfunction.

- 33. (New) Use according to claim 26, characterized in that the medicament is suitable for oral administration.
- 34. (New) Use according to claim 33, characterized in that the medicament is in the form of a tablet, a capsule or a suspension.
- 35. (New) Use according to claim 33, characterized in that the medicament is in form of multiparticulates, preferably pellets or granules, optionally compressed into a tablet, filled into a capsule or suspended in a suitable liquid.
- 36. (New) Use according to claim 26, characterized in that the medicament comprises at least one of the compounds of general formula I at least partially in a sustained-release form.
- 37. (New) Use according to claim 36, characterized in that the medicament has at least one coating or matrix comprising at least one sustained-release material.
- 38. (New) Use according to claim 37, characterized in that the sustained-release material is based on an optionally modified, water-insoluble, natural, semisynthetic or synthetic polymer, or a natural, semisynthetic or synthetic wax or fat or fatty alcohol or fatty acid, or on a mixture of at least two of these afore mentioned components.

- 39. (New) Use according to claim 38, characterized in that the water-insoluble polymer is based on an acrylic resin, which is preferably selected from the group of poly(meth) acrylates, poly(C_{1-4})dialkylamino(C_{1-4})alkyl (meth) acrylates and/or copolymers thereof or a mixture of at least two of the aforementioned polymers.
- 40. (New) Use according to claim 38, characterized in that the water-insoluble polymers are cellulose derivatives, preferably alkyl cellulose and particularly preferably ethyl cellulose, or cellulose esters.
- 41. (New) Use according to claim 38, characterized in that the wax is carnauba wax, beeswax, glycerol monostearate, glycerol monobehenate, glycerol ditripalmitostearate, microcrystalline wax or a mixture of at least two of these components.
- 42. (New) Use according to claim 38, characterized in that the polymers have been used in combination with one or more plasticizers.
- 43. (New) Use according to claim 32, characterized in that the medicament comprises an enteric coating.
- 44. (New) Use according to claim 26, characterized in that the medicament comprises at least one immediate-release coating comprising at least one of the compounds of general formula I.